



# IN STRIDE

The Official Magazine of the United States Hunter Jumper Association


**Record Prize Money**  
**Pre-Green Incentive Championship**

## **Liza Boyd & Brunello**

*Make Derby History*



**Porter Brothers  
NAJYRC Gold  
Medalists**



**Hares Explained**

## Zones 1/9 and 3 Take Team Gold at NAJYRC

The Adequan/FEI North American Junior and Young Rider Show Jumping Championship, presented by the United States Hunter Jumper Association, welcomed 65 athletes ages 14 to 21 from Canada, the Dominican Republic, Mexico and the United States to the Kentucky Horse Park in July for four days of team and individual competition.

A combined team from Zones 1 and 9 (Conington/Sara Nordstrom, HS Classic Care/McKayla Langmeier, Lord Levisto/Jennifer Gates, Aletta/Victoria Arute) took the gold in the Junior division over Zone 5 and Mexico. Zone 3 (Arwen/Christina Firestone, Toluca LS/Alison Cooney, Mastermind/KC Van Aarem, Athena/Chloe Reid) dominated to take gold in the Young Rider division, while Zone 4 took silver and Zone 2 bronze.

The courses, designed by Olympic Games course designer Steve Stephens, proved difficult for both divisions, especially the Young Riders. The Junior division saw four double-clear efforts by Adrien Vilcini (Zone 10), Lucas Porter (Zone 7), Sara Nordstrom (Zone 9) and Lucy Deslauriers (Zone 2).

"The course was challenging but not unfair," said Sara Nordstrom, a past participant in the USHJA Emerging Athletes Program National Training Session. "I owe it all to my horse; he jumped beautifully. But I didn't feel good until after the very last jump in both rounds!"

The Young Riders competed over a slightly different course that many had trouble navigating. Michael Hughes' superb double-clear performance with Luxina helped his Zone 2 team win the bronze with 46 faults. Zone 4 earned the silver medal with 35 faults, but it was the ladies of Zone 3 who were unstoppable, earning the gold medal on a score of 14 faults.

"Our Chef d'Equipe, Sandra [Ruiz], has a lot of energy and is very inspirational, so giving this back to her means a lot," said Chloe Reid of Zone 3. Reid noted



ADEQUAN/FEI  
NORTH AMERICAN  
JUNIOR  
& YOUNG  
RIDER  
CHAMPIONSHIPS  
PRESENTED BY GOTHAM NORTH



MCMILLEN PHOTOGRAPHY

The Zone 3 NAJYRC Young Rider Show Jumping team (from left, Allison Cooney, K.C. Van Aarem, Coach Sandra Ruiz, Christina Firestone and Chloe Reid) made history with their first team gold medal.

that Ruiz pointed out after their win that it was the first time that Zone 3 has won a team medal at NAJYRC.

But not all of the Zone 3 riders thought they would be on the podium. KC Van Aarem of Maryland said she purchased her 12-year-old Canadian Sport Horse gelding Mastermind through an Internet ad with the intention of competing in the ASPCA Maclay equitation classes.

"It's been a great experience, but I wasn't expecting to be here today," said Van Aarem. "I bought [Mastermind] to be a 3' hunter!"

The USHJA is proud to be the presenting sponsor of Show Jumping for the Adequan/FEI North American Junior and Young Rider Championships, presented by Gotham North, and recognizes the importance this program plays in the

development of our sport's future top athletes.

To read about brothers Lucas and Wilton Porter, the individual Junior and Young Rider gold medalists, please see page 39.

## Horsemanship Challenge Winners Announced

More than 250 trainers had students participating in this year's USHJA 30-Day Horsemanship Stable Challenge, with 312 members, competition ages 20 and younger, taking part from all 12 Zones.

Teams of at least three junior and/or amateur students per trainer signed up to take the online Horsemanship Quiz Challenge Practice Quiz from June 15-July 15. At the end of the 30-Day Horsemanship Stable Challenge, the

three top scores under each trainer were averaged to provide an overall score, with the highest scoring trainer in each zone declared the champion. In order to be eligible for the grand prize, trainers must be USHJA members.

With nine of the 12 Zones fielding complete teams of three students per trainer, the champions were:

**Zone 1:** Alicia Bessoni, Gina Leavitt, Kelly Merry of Glastonbury Hunt Club

**Zone 2:** Denise Van Patten of Smoke Tree Farm

**Zone 3:** Jenn Fessler of Steep Forest Farm

**Zone 4:** Ashley Fant of Marigny Park Stables

**Zone 5:** Diane McClure of Gateway Farm

**Zone 7:** Lindsey Lamb of KJM Equestrian

**Zone 9:** Linda Worley of Cornerstone Hunters and Jumpers

**Zone 10:** Elizabeth Evans of Mischief Farm

**Zone 12:** Jaimie Thurman of Forever Young Farm

The 30-Day Horsemanship Stable Challenge, which debuted in 2013, is an engaging way to encourage trainers and their students to become involved in the Horsemanship Quiz Challenge. The 2014 HQC Finals will be held November 14-16, at the University of Findlay in Findlay, Ohio, in conjunction with the USHJA Emerging Athletes Program National Training Session.

## Madden Makes History in King George V Gold Cup

After 108 years, it was U.S. Olympic Games double gold medalist Beezie Madden who jumped through the glass ceiling by becoming the first female to claim victory in the Longines King George V Gold Cup at the CSIO5\* Hickstead (England).



PAUL HARDING

Beezie Madden celebrated her Longines King George V Gold Cup victory aboard Cortes C.

### Brief Summary of Prescribing Information

## DORMOSEDAN GEL

(detomidine hydrochloride)  
Alpha<sub>2</sub>-agonist oromucosal gel

**Rx only**  
For Sedation and Restraint in Horses Only

**CAUTION:**  
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**INDICATIONS:**  
DORMOSEDAN GEL is indicated for sedation and restraint in horses.

**DOSAGE AND ADMINISTRATION:**  
DORMOSEDAN GEL produces sedation when administered sublingually at 0.018 mg/lb (0.040 mg/kg). DORMOSEDAN GEL must be placed beneath the tongue of the horse and is not meant to be swallowed. The dosing syringe delivers the product in 0.25 mL increments. The following dosing table may be used to determine the correct dose of DORMOSEDAN GEL (Table 1).

#### Table 1: Sublingual dosing of DORMOSEDAN GEL

Approx. body weight (lb)	Range of doses (mg/lb)	Approx. body weight (kg)	Range of doses (mg/kg)	Dose volume (mL)
330-439	0.023-0.017	150-199	0.051-0.038	1.00
440-549	0.022-0.017	200-249	0.047-0.038	1.25
550-659	0.021-0.017	250-299	0.046-0.038	1.50
660-769	0.020-0.017	300-349	0.044-0.038	1.75
770-879	0.019-0.017	350-399	0.043-0.038	2.00
880-989	0.019-0.017	400-449	0.043-0.038	2.25
990-1099	0.019-0.017	450-499	0.042-0.038	2.50
1100-1209	0.019-0.017	500-549	0.042-0.038	2.75
1210-1320	0.019-0.017	550-600	0.041-0.038	3.00

Use impermeable gloves when handling the product. Remove the syringe from the outer carton. While holding the plunger, turn the ring-stop on the plunger until the ring is able to slide freely up and down the plunger. Position the ring in such a way that the side nearest the barrel is at the desired volume marking. Turn the ring to secure it in place. Make sure that the horse's mouth contains no feed. Remove the cap from the tip of the syringe and save for cap replacement. Insert the syringe tip into the horse's mouth from the side of the mouth, placing the syringe tip beneath the tongue at the level of the commissure of the mouth. Depress the plunger until the ring-stop contacts the barrel, depositing the product beneath the tongue. Take the syringe out of the horse's mouth, recap the syringe and return it to the outer carton for disposal. Remove gloves for disposal.

For the best results, allow adequate time (a minimum of 40 minutes) between administration of DORMOSEDAN GEL, and beginning the procedure. In general, horses show sedative effects lasting approximately 90-180 minutes.

Withhold food and water until the sedative effects of the product wear off.

#### CONTRAINDICATIONS:

DORMOSEDAN GEL is contraindicated in horses with known hypersensitivity to detomidine. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur.

Do not use DORMOSEDAN GEL in horses with pre-existing atrioventricular (AV) or sino-atrial (SA) blocks, respiratory disease, or chronic renal failure.

#### WARNINGS:

For sublingual use in horses only. Do not use in horses intended for human consumption.

**HUMAN WARNINGS:** Not for human use. Keep out of the reach of children. **Use impermeable gloves during drug administration and during procedures that require contact with the horse's mouth.** Following sublingual administration of detomidine oromucosal gel, drug concentrations up to 0.072 mg/mL were measured at 30 minutes post dose in equine saliva, equivalent to less than one percent of the original detomidine concentration in the gel. Mean drug concentrations fall to less than 0.010 mg/mL by 2 hours after drug administration, after which a slow decline occurs for several additional hours.

DORMOSEDAN GEL can be absorbed following direct exposure to skin, eyes, or mouth, and may cause irritation. Skin and mucosal contact with the product should be avoided. Use impermeable gloves at all times.

In case of accidental eye exposure, rinse abundantly with fresh water. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing.

Appropriate precautions should be taken while handling and using gel syringes. Accidental exposure could cause adverse reactions, including sedation, hypotension, and bradycardia. Seek medical attention immediately but do not drive because sedation or changes in blood pressure may occur.

Individuals with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid exposure to this product.

Caution should be exercised when handling sedated horses. Handling or any other sudden stimuli, including noise, may cause a defense reaction in an animal that appears to be heavily sedated.

Rare cases of human abuse of detomidine products have been reported. DORMOSEDAN GEL should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting.

The material safety data sheet (MSDS) contains more detailed occupational safety information. To report adverse reactions in users or to obtain a copy of the MSDS for this product call 1-800-366-5288.

**Note to physician:** This product contains an alpha<sub>2</sub>-adrenoceptor agonist.

#### PRECAUTIONS:

DORMOSEDAN GEL must be placed beneath the tongue of the horse. Unlike most oral veterinary products, this product is not meant to be swallowed. Swallowing could result in ineffectiveness.

DORMOSEDAN GEL does not provide analgesia. Do not use for painful procedures.

Do not use with other sedative drugs because the effects may be additive.

Repeat dosing has not been evaluated.

The use of an alpha<sub>2</sub>-agonist reversal agent with DORMOSEDAN GEL has not been evaluated.

Before initiating any procedure, allow sedation to fully develop. Nervous or excited horses with high levels of endogenous catecholamines may exhibit a reduced pharmacological response to alpha<sub>2</sub>-adrenoceptor agonists like detomidine. In agitated horses, the onset of sedative effects could be slowed, or the depth and duration of effects could be diminished or nonexistent. When the product is administered, the animal should be allowed to rest in a quiet place for a minimum of 40 minutes.

Do not use DORMOSEDAN GEL in horses with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes.

As with all alpha<sub>2</sub>-adrenoceptor agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists.

DORMOSEDAN GEL has not been evaluated in ponies, miniature horses, or horses younger than one year of age.

DORMOSEDAN GEL has not been evaluated for use in breeding, pregnant, or lactating horses.

#### ADVERSE REACTIONS:

##### Clinical field study:

In a US field study of 270 horses sedated to facilitate completion of various veterinary and husbandry procedures, the following adverse reactions were reported in 202 horses treated with DORMOSEDAN GEL and 68 horses treated with placebo:

Table 2: Adverse reactions (number of horses) during the clinical field study

Clinical Sign	DORMOSEDAN GEL N = 202	Placebo N = 68
Sweating	20	0
Penile relaxation	12	0
Bradycardia (≤ 20 bpm)	11	0
Second degree AV block	9	0
Frequent urination	9	0
Piloerection	4	0
Marked ataxia	3	0
Facial/oral edema	3	0
Hypersalivation	2	0
Nasal discharge	2	0
Flatulence	1	0
Muscle tremors	1	1
Epiphora	1	0
Pale mucous membranes	1	0
Swollen sheath	1	0

In a laboratory study, transient erythema of the mucous membranes was seen in 2 (of 8) horses that received the recommended dose of detomidine gel.

Mild ataxia (horse stable but swaying slightly) was observed in 54% of DORMOSEDAN GEL-treated horses and in 4% of the placebo-treated horses at 40 minutes post treatment administration. Moderate ataxia was observed in 25% of DORMOSEDAN GEL-treated horses (0% placebo) at 40 minutes post treatment. Moderate to marked ataxia continued to 90 minutes for 5% and to 120 minutes for 4% of DORMOSEDAN GEL-treated horses.

#### STORAGE INFORMATION:

Store at controlled room temperature 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F), in the original package.

#### HOW SUPPLIED:

3.0 mL graduated oral dosing syringe, 7.6 mg/mL detomidine hydrochloride.

DORMOSEDAN is a trademark of Orion Corporation.

Mfg by:



Dist by:



Pfizer Animal Health  
Div. of Pfizer Inc  
New York, NY 10017

Made in Finland  
Date: December 2, 2009

DOR1200